The following presentation from the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, summarises the findings regarding the treatment of sarcomatoid renal cell carcinoma (RCC) presented in three papers at the meeting.
Around 10-20% of patients with advanced RCC are thought to have sarcomatoid histology. Tumours with sarcomatoid histology have a limited response to targeted therapies. Sarcomatoid histology is predominantly found in stage IV tumours, and is a predictor of poor survival. However, this summary presents data to show improved outcomes following treatment with immune checkpoint inhibitors.